<DOC>
	<DOC>NCT01878344</DOC>
	<brief_summary>The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy. In a sub-group of patients coronary flow reserve will be evaluated.</brief_summary>
	<brief_title>Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Patients with Acute ST Elevation Myocardial Infarction undergoing Primary Percutaneous Coronary intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy (Mehran Score â‰¥5) Patients &gt;18 years old with moderate to high risk for contrast induced nephropathy undergoing percutaneous coronary intervention Low risk for contrast induced nephropathy (Mehran Score &lt;5) Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...) Infection Pregnancy, Lactation Renal failure requiring dialysis Hepatic failure Allergy to NAC History of Asthma Chronic nitrate usage Malignancy Use of corticosteroids Leucocytosis,Thrombocytosis,Anemia Blood pressure of &gt;180/100mmHg despite antihypertensive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>